PubRank

Sian Fereday

Author PubWeight™ 47.15‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010 13.07
2 Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008 8.17
3 Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 2010 5.23
4 BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012 3.86
5 Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2012 3.64
6 Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009 3.45
7 Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol 2013 2.48
8 ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol 2013 1.61
9 Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013 1.47
10 LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin. Cancer Res 2012 1.39
11 ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Clin Cancer Res 2008 1.33
12 Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008 1.05
13 Reducing time to diagnosis does not improve outcomes for women with symptomatic ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2011 0.93
14 High levels of genomic aberrations in serous ovarian cancers are associated with better survival. PLoS One 2013 0.82
15 Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature 2015 0.75